Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
    • Transskriptioner
    • AGM Invitations
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

SynAct Pharma

17,80 SEK

-1,87 %

Mindre end 1K følgere

SYNACT

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Dividend
Investorkonsensus
Sammenligne
-1,87 %
-8,62 %
-21,24 %
-16,43 %
-6,51 %
+15,96 %
-73,19 %
-65,30 %
+286,15 %

SynAct Pharma operates in the pharmaceutical industry and focuses on the development of innovative treatments for inflammatory diseases. The company researches new therapies that can reduce inflammation and improve patient outcomes. The business is global with a primary presence in Europe and North America. SynAct Pharma was founded in 2012 and is headquartered in Lund, Sweden.

Læs mere
Markedsværdi
949,28 mio. SEK
Aktieomsætning
1,33 mio. SEK
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
27.5
2026

Delårsrapport Q1'26

11.6
2026

Generalforsamling '26

20.8
2026

Delårsrapport Q2'26

Alle
Selskabspræsentationer
Selskabsmeddelelser
Eksterne analyser
ViserAlle indholdstyper
Pressemeddelelse4.3.2026, 11.00

Invitation to SynAct Pharma’s Capital Markets Day in Stockholm March 11

SynAct Pharma
Eksterne analyser4.3.2026, 06.27

Synact Pharma: Multiple shots on goal in 2026 for resomelagon - Edison

SynAct Pharma’s FY25 results reflect a year of solid execution, highlighted by the continued advancement of lead asset resomelagon in the Phase IIb ADVANCE trial in rheumatoid arthritis (RA). With enrolment completed in February 2026 (n=246), top-line...

SynAct Pharma
Pressemeddelelse3.3.2026, 15.25

Redeye: SynAct Pharma: Interview about the directed share issue

SynAct Pharma

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Pressemeddelelse3.3.2026, 15.23

Redeye: SynAct Pharma: Cash Position Further Strengthened

SynAct Pharma
Pressemeddelelse3.3.2026, 07.43

BioStock: SynAct Pharma secures 51,9 million SEK to strengthen clinical runway

SynAct Pharma
Selskabsmeddelelse2.3.2026, 22.20

SynAct Pharma has carried out a directed issue of new shares of approximately 51.9 MSEK

SynAct Pharma
Selskabsmeddelelse2.3.2026, 16.37

SynAct Pharma announces intention to carry out a directed issue of approximately 45 MSEK

SynAct Pharma
Selskabsmeddelelse24.2.2026, 09.00

SynAct Pharma appoints Ann Kristin Led as Chief Financial Officer

SynAct Pharma
Pressemeddelelse20.2.2026, 07.40

BioStock: Topline results on the horizon for SynAct Pharma

SynAct Pharma
Pressemeddelelse19.2.2026, 06.41

BioStock: SynAct Pharma on dual studies, partner interest and commercial potential

SynAct Pharma
Selskabsmeddelelse18.2.2026, 06.30

SynAct Pharma Year-end Report 2025

SynAct Pharma
Selskabsmeddelelse17.2.2026, 16.30

Repurchase of shares in Synact Pharma AB

SynAct Pharma
Pressemeddelelse9.2.2026, 11.00

SynAct Pharma to host Capital Markets Day in Stockholm on March 11

SynAct Pharma
Pressemeddelelse9.2.2026, 09.58

Redeye: SynAct Pharma: Last Patient Included

SynAct Pharma
Pressemeddelelse6.2.2026, 16.30

SynAct Pharma successfully reached recruitment goal in Ph2b ADVANCE study

SynAct Pharma
Pressemeddelelse30.1.2026, 16.30

SynAct Pharma initiates Phase 2 study in respiratory insufficiency

SynAct Pharma
Selskabsmeddelelse19.1.2026, 07.00

SynAct Pharma appoints Malin Wikstrand as interim CFO

SynAct Pharma
Selskabsmeddelelse9.1.2026, 18.16

The Board of Directors of SynAct Pharma AB (publ) has resolved on the repurchase of own shares

SynAct Pharma
Pressemeddelelse2.1.2026, 13.00

BioStock: SynAct Pharma kicks off 2026 ahead of ADVANCE results

SynAct Pharma
Pressemeddelelse23.12.2025, 07.00

SynAct Pharma Board of Directors and Management Enter Lock-up Agreements

SynAct Pharma
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.